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The lack of proven screening tools for early detection and the high mortality of ovarian serous carcinoma (OSC), particularly high
grade, have focused attention on identifying putative precursor lesions with distinct morphological and molecular characteristics.
The ﬁnding of occult invasive and intraepithelial fallopian tube carcinomas in prophylactically removed specimens from
asymptomatic high-risk BRCA 1/2-mutation carriers supports the notion of an origin for OSC in the fallopian tube. The
intraepithelial carcinomas have been referred to as serous intraepithelial carcinomas (STICs) but our own ﬁndings (unpublished
data) and recent reports have drawn attention to a spectrum of changes that fall short of STICs that we have designated serous
tubal intraepithelial lesions (STILs).
1.Introduction
Ovarian cancer is the most lethal gynecologic cancer,
responsible for over 13,000 deaths in the US in 2009
(http://www.cancer.org/). The majority of these cancers
are detected at an advanced stage, after they have spread
to the peritoneal surfaces; the 5-year survival rate for
women diagnosed at stage III-IV is only 28% (SEER Can-
cer Statistics Review, 1975–2004, National Cancer Institute
http://seer.cancer.gov/csr/1975 2006/). A lack of eﬀective
screening tools for early detection of ovarian cancer in high-
risk and general populations has led to increased interest
in the identiﬁcation of precursor lesions deﬁned by both
morphological and molecular changes that could be the
target of not only early detection but prevention eﬀorts.
2. Molecular Characteristicsof OvarianCancer
Ovarian cancer is heterogeneous, like other cancers, com-
prising a collection of subtypes with diﬀerent histologic and
molecular characteristics that in turn inform prognosis [1].
Accumulating evidence suggests that there are two general
pathways in the molecular pathogenesis of what is known
as ovarian cancer [2, 3]. The ﬁrst (Type I) pathway leads to
borderline tumors, which can develop into low-grade serous,
mucinous, endometrioid, and clear cell carcinomas. These
areforthemostpartlow-gradetumorsthatarecharacterized
by a high frequency of mutations of KRAS, BRAF, ERBB2,
CTNNB1(thegeneencodingbetacatenin),andPIK3CA,lo w
proliferation, and a 5-year survival of approximately 55%
[2]. A stepwise model of progression from cystadenomas
to low-grade carcinomas has been proposed for these
neoplasms.
In contrast to the Type I tumors, the Type II tumors
are high-grade and highly aggressive, spreading rapidly
throughout the pelvis. Type II tumors include high-grade
serous carcinoma, malignant mixed mesodermal tumors,
and undiﬀerentiated carcinomas. They are characterized by
a high frequency of mutations in TP53, a tumor suppressor
gene, and a high proliferative index. It is estimated that 60%
of sporadic ovarian carcinomas and the majority of those
diagnosed in BRCA1 mutation carriers are of the high-grade
serous type [4, 5]. Preliminary data suggests that these TP53
mutations may develop early in the carcinogenic process. If2 Journal of Oncology
in fact this is conﬁrmed, new approaches to early detection
and prevention can be developed.
3.Identifying the Cellof Origin
It has conventionally been assumed that ovarian cancers
arise from the ovarian surface epithelium (OSE), which is
viewed as a modiﬁed type of mesothelium similar to that
which lines the peritoneal cavity, by a process of invagination
leadingtothedevelopmentofcorticalinclusioncysts(CICs).
It has been argued that changes in the microenvironment
of the ovarian stroma surrounding the CICs leads to
m¨ ullerian-type diﬀerentiation. This step, which is viewed
as a metaplastic change, would be necessary to explain
the morphologic appearance of ovarian epithelial tumors
which have a m¨ ullerian-type phenotype. However, others
believe it is unlikely that CICs are precursors and have
instead proposed that ovarian epithelial tumors develop
from m¨ ullerian-type epithelium lining paraovarian and
paratubal cysts (the so-called secondary m¨ ullerian system)
[6]. A tubal origin for high-grade serous ovarian cancer is
supported by gene expression proﬁles of OSC that reveal that
they are more similar to normal m¨ ullerian epithelium than
the ovarian surface epithelium [7].
4. ProphylacticSalpingo-Oophorectomy in
BRCA1 andBRCA2 MutationCarriers
Prophylactic bilateral salpingo-oophorectomy (BPSO) speci-
mens from high-risk women have proved to be an invaluable
resource for research into the origins and precursors for
high-grade serous pelvic carcinomas. Women found to have
a deleterious germline mutation in the BRCA1 or BRCA2
gene are known to be at increased risk for ovarian cancer,
with lifetime risk estimates ranging from 40% to 60% [8,
9]. Given the limitations of current options for ovarian
surveillance, bilateral prophylactic salpingo-oophorectomy
(BPSO) after the completion of child-bearing is the current
standard recommendation for these women [10]. This pro-
cedure greatly reduces the risk of subsequent development
of pelvic serous carcinoma, by 80%–90%, but surprisingly
does not eliminate it entirely [11]. Remaining risk is mainly
attributed to primary peritoneal serous carcinoma, which
is similar to high-grade OSC in terms of presentation and
response to treatment [12] and appears to originate from the
same cell lineage [11]. The estimated cumulative incidence
of peritoneal cancer at 20 years after oophorectomy is 4.3%
[13],andsofarasurvivalbeneﬁthasbeenshownintheshort
term but not long term [14].
5. Occult Carcinoma
It is estimated that between 2% and 17% of all BPSO
specimens from BRCA1/2 mutation carriers will contain
an occult cancer (see Table 1). The range of estimates to
some extent is reﬂective of the comparison groups and
the protocols used for sectioning specimens [11, 13, 15–
24]. Despite these inconsistencies a majority of early serous
cancers found in these specimens are localized to the
fallopian tube.
6.SerousTubal IntraepithelialCarcinomas
High-grade serous tubal intraepithelial carcinomas (STICs)
are noninvasive carcinomas of the fallopian tube that have
been found with varying frequency in BPSO specimens (see
Table 2).STICsarecharacterizedmorphologicallybynuclear
hyperchromasia and atypia, mitotic ﬁgures, and nuclear
stratiﬁcation [26]. Immunohistochemically, they exhibit
increasedstainingforp53andMIB-1(Ki-67)[26](Figure 1).
As noted above, many of the occult malignancies detected on
thorough sectioning of BPSO specimens were microscopic
and restricted to the fallopian tube. Subsequently, a careful
and thorough examination of the fallopian tubes from 55
consecutive cases of “serous carcinoma” (pelvic, ovarian, or
tubal) revealed that over 70% involved the endosalpinx and
approximately half contained STICs [27]. These ﬁndings led
to the hypothesis that the fallopian tube may be the source
of a signiﬁcant proportion of all pelvic high-grade serous
carcinomas. To further conﬁrm the shared origin of these
OSC with their coexisting STICs, the authors analyzed p53
mutations in both sites from ﬁve cases. Identical mutations
were detected in both sites for all cases. An analysis of
chromosomal copy number changes by FISH demonstrated
similar results in 3/5 cases comparing ovarian serous tumors
with synchronous fallopian tube serous carcinoma, pro-
viding some additional potential support for a common,
monoclonal origin [28]. Further, another study from the
same group examined 45 cases of primary peritoneal serous
carcinoma and found that 9 out of 26 cases with incomplete
tubal sampling and 9 out of 19 cases that underwent
complete examination of the tube had STIC [29]. In all
of these studies, the majority of STICs were found in the
ﬁmbriated end of the tube, adjacent to the ovarian surface.
In an eﬀort to verify the ﬁmbria as a preferred site for
STICs in BPSO specimens, Medeiros et al. [25]i n v e s t i g a t e d
13 BRCA+ BPSOs and 13 controls, who were women
who had bilateral salpingo-oophorectomy due to other
gynecological diseases. Six of the cases had mutations in
BRCA1 and 7 were BRCA2 positive. Cases and controls
had similar age ranges and mean ages (50 and 58 years,
resp.), and all specimens were entirely submitted for review,
sectioned at 2-3mm intervals. In addition, all ﬁmbriae were
extensively sectioned in one of two ways: serial sectioning (7
cases) or by SEE-FIM protocol—Sectioning and Extensively
ExaminingtheFimbriae—in19cases.TheSEE-FIMprotocol
wasdevelopedtoensuremaximalexaminationoftheﬁmbria
[25]. Cases were compared to controls for the rate of
detection of early neoplasms, their locations, and expression
patterns for p53 and Ki-67. Five cancers were identiﬁed, all
of which were tubal and from the case group. Four of the ﬁve
tumors involved the ﬁmbria; four of these ﬁve also stained
positive for both p53 (>75% nuclei staining positive in a
region of 12 cells in length) and Mib-1. The reason for the
tendency of these early cancers to be found in the ﬁmbria is
not entirely clear, but the authors suggest that it may be dueJournal of Oncology 3
Table 1: Prevalence of occult carcinoma in bilateral prophylactic salpingo-oophorectomy specimens.
Author Study design Study population Sectioning protocol Findings
Colgan et al. 2001 [15] Cross-sectional
60 BPSO specimens
from women (mean age
48.4) with high
likelihood of being
BRCA mutation carriers
according to family
history (early criteria) or
tested positive for a
BRCA1 or BRCA2
mutation (later criteria)
Ovaries: multiple
sections through the
short axis; fallopian
tubes: 40/60 had
representative sections
only, the other 20 were
completely submitted
with transverse sections
5 (8.3%) cases showed
occult carcinoma; 4/5
located in fallopian tube
Leeper et al. 2002 [17] Cross-sectional
30 BPSO specimens
from women (mean age
46, range 30–65) at high
risk of ovarian cancer
according to family or
personal history
Ovaries and tubes: ﬁrst 7
cases had representative
sections only, remaining
23 cases were serially
sectioned
5 (16.7%) cases showed
occult carcinoma; 3
located in fallopian tube
Olivier et al. 2004 [18] Cross-sectional
38 BPO specimens and
90 BPSO specimens
from women (mean age
46, range 26–74) with
known BRCA1 or
BRCA2 mutations or
personal history of
breast cancer and family
history suggestive of
hereditary breast and
ovarian cancer
Ovaries from all
procedures and tubes
from BPSO procedures:
sectioned in their
entirety
5 (5.6%) cases from
BPSO group showed
occult carcinoma (all in
BRCA1 carriers); 2
restricted to the fallopian
t u b e ;n oo c c u l tc a n c e r s
in ovary-only specimens
Lamb et al. 2006 [22] Cross-sectional
113 BPSO specimens
from women (median
age 47, range 30–70) at
high risk for ovarian
cancer based on GOG
criteria
Ovaries and tubes:
sectioned at 2- to 3-mm
intervals
7 (6.2%) cases showed
ovarian, fallopian tube
or peritoneal neoplasia;
5 were early high-grade
serous tubal neoplasia
Finch et al. 2006 [21] Cross-sectional
159 BPSO specimens
from BRCA1 or BRCA2
mutation carriers (mean
age 47.7, range 34–71)
Ovaries: serially
sectioned; fallopian
tubes initially
representative
sections—partway
through protocol
amended to submit
tubes in entirety
7 (4.4%) cases showed
occult carcinoma; 6
involved fallopian tube
Medeiros et al. 2006 [25] Case-control
13 BPSO specimens
from BRCA1 or BRCA2
mutation carriers (mean
age 50, range 39–76) and
13 controls (mean age
58, range 43–76)
undergoing surgery for
benign reasons
Ovaries and tubes:
sectioned at 2- to 3-mm
intervals; ﬁmbriae in
some cases serially
sectioned, in others by
SEE-FIM protocol
5 (38%) cases showed
early cancers; all in the
fallopian tube; 4/5
stained positive for both
p53 and MIB-1, the 5th
scored positive for
MIB-1 only; no cancers
were found in controls
Hermsen et al. 2006 [24] Case-control
85 BPSO specimens
from high-risk women
according to family
history or BRCA1 or
BRCA2 mutation status
(median age 48, range
33–64) and 72 controls
undergoing surgery for
benign reasons (median
age 37, range 23–79)
Sectioning details not
speciﬁed
1 case of tubal
carcinoma + 2 cases of
severe tubal dysplasia/in
situ carcinoma (3.5%)
were identiﬁed in the
BPSO group; no cancers
were found in controls4 Journal of Oncology
Table 1: Continued.
Author Study design Study population Sectioning protocol Findings
Callahan et al. 2007 [23] Cross-sectional
122 BPSO specimens
from women with
BRCA1 or BRCA2
mutations or variants
(median age 46.5, range
23–76)
Ovaries and tubes:
sectioned at 2- to 3-mm
intervals for all cases;
SEE-FIM protocol
performed in a subset
7 (5.7%) cases showed
occult tubal carcinoma
Finch et al. 2006 [13] Cross-sectional
490 BPSO specimens
from women with
BRCA1 or BRCA2
mutations (mean age
47.6, range 19–76)
A l lr e p o r t e dc a n c e r s
conﬁrmed by review of
medical records and/or
pathology reports. The
pathology reports were
reviewed in order to
correctly assign the
diagnosis of ovarian,
fallopian tube, or
primary peritoneal
cancer.
11 (2.2%) specimens
showed occult cancer; 7
were identiﬁed as
ovarian; 3 were classiﬁed
as tubal; 1 case had
positive peritoneal
washings with no source
of cancer identiﬁed
Powell et al. 2005 [19] Cross-sectional
67 BPSO specimens
from women with
BRCA1 or BRCA2
mutations (mean age 47,
range 31–64)
Ovaries and tubes:
serially sectioned at
2mm intervals (“full”
adherence to speciﬁed
protocol) in 20 cases;
partial adherence in 21
cases; standard
procedures
(nonadherence) in 26
cases
7 (17%) specimens that
were processed by fully
or partially adherent
protocols (n = 41)
showed occult cancer; 4
were tubal and 3 were
ovarian
BPO: bilateral prophylactic oophorectomy; BPSO: bilateral prophylactic salpingo-oophorectomy; GOG: gynecologic oncology group; SEE-FIM: sectioning
and extensively examining the ﬁmbriae.
to increased surface area of this site, or potential diﬀerences
in characteristics of the cells from this region versus more
proximal sections of the tube. Their ﬁndings support a
possible means of spread to the ovary by exfoliation or tubal-
ovary adhesions.
7. Resemblance of STIC to Serous Endometrial
IntraepithelialCarcinoma
Like high-grade OSC, uterine serous carcinomas are aggres-
sive cancers with poor prognosis [30, 31]. Despite com-
prising only 10%–15% of all endometrial carcinomas, USC
causes a disproportionate number of deaths and appears to
have a diﬀerent etiologic pathway than the usual type of
endometrial carcinoma (endometrioid adenocarcinoma). In
contrasttotheendometrioidtype,whichistypicallyfoundto
be associated with endometrial hyperplasia and other signs
of hyperestrogenism, most uterine serous carcinomas are
diagnosed in older, postmenopausal women with atrophic
endometrium and no evidence of endometrial hyperplasia.
It has therefore been hypothesized that uterine serous car-
cinoma and its presumptive precursor, serous endometrial
intraepithelial carcinoma, may originate in an estrogen-
independent manner [32] and are associated with other
factors [33].
Serous endometrial intraepithelial carcinoma (SEIC)
is characterized by “replacement of endometrial surface
epithelium and glands by malignant cells that resemble
invasive high-grade endometrial carcinoma” [34]. It has
been identiﬁed in greater than 90% of uteri containing
serous carcinoma [31]. Interestingly, immunostaining for
p53 expression in pairs of uterine serous carcinoma with
SEIC showed the majority to be p53 positive and all pairs
were concordant [34]. Shared p53 mutations have also
been described in SEIC and the associated uterine serous
carcinoma [35]. Uterine serous carcinoma and OSC both
exhibit a tendency to spread rapidly throughout the pelvis
and multifocal disease is often found at diagnosis. These
multiple foci are thought to represent monoclonal disease,
unlike endometrioid carcinomas, which have been shown to
have multiple sites of origin [36]. The question of site of
origin for these multifocal uterine serous carcinoma parallels
that of the origin of other pelvic serous carcinomas.
A recent study attempted to document the frequency
of concurrent STIC and SEIC, conjecturing that uterine
serouscarcinomawithSTICmightrepresentadistinctsubset
of pelvic serous carcinomas, with as-yet unclear origin. Of
22 uterine serous carcinoma cases examined, the presence
of STIC was conﬁrmed in 5 [36]. It was found that the
endometrial tumor in all ﬁve of these cases was either
noninvasive or superﬁcially invasive, and in 2 of the cases
identical p53 mutations were identiﬁed in both tubal andJournal of Oncology 5
Table 2: Serous tubal intraepithelial carcinoma in pelvic serous carcinoma cases.
Author Study design Study population Sectioning Protocol Findings
Salvador et
al. 2008 [28]
Cross-sectional
16 cases of epithelial
ovarian malignancy with
tubes submitted in toto
fallopian tubes
s u b m i t t e di nt o t oa n d
serially sectioned every
3-4mm
10 of the 12 cases of high-grade
serous carcinoma showed either
unilateral tubal mucosal
involvement by TIC (n = 7) or
tubal obliteration ipsilateral to
the dominant ovarian mass
(n = 3). In 3 of 5 selected high
grade serous carcinoma cases
with TICs, FISH analysis showed
similar copy number changes in
foci of the ovarian and fallopian
tube mucosal carcinoma; one
case was not synchronous and
the 5th was indeterminate
Kindelberger
et al. 2007
[27]
Cross-sectional
55 cases containing
pelvic serous carcinoma
(mean age 61.5, range
43–82)
SEE-FIM for all cases
41(75%) showed involvement of
endosalpinx; 11 were classiﬁed as
tubal or peritoneal primary; (9 of
these had TICs); 20/30 cases
classiﬁed as ovarian had TICs;
93% of TICs involved the
ﬁmbria. Of 5 ovarian cases with
TICs, p53 DNA analysis showed
identical mutations in at least
one focus of TIC and ovarian
cancer
Carlson et al.
2008 [29]
Cross-sectional
45 cases of primary
peritoneal serous
carcinoma in which
there was either
nonuniform sampling of
the fallopian tube
(n = 26) or SEE-FIM
protocol (n = 19)
nonuniform sampling
(portion of tube
submitted), or SEE-FIM
protocol
9 (35%) of ﬁrst sampling group
and 9 (47%) of second samping
group showed STICs. 5/5 cases
tested showed identical p53
mutations in the peritoneal and
tubal lesions
FISH:ﬂuorescenceinsituhybridization;SEE-FIM:sectioningandextensivelyexaminingtheﬁmbriae;STIC:seroustubalintraepithelialcarcinoma;TIC:tubal
intraepithelial carcinoma.
endometrial lesions, suggesting a common origin, perhaps
in the tube, for these cases. The proposal that these uterine
tumors may also be of tubal origin is intriguing and certainly
deserves further investigation.
8. Identiﬁcation of PrecursorLesions
8.1. Serous Tubal Intraepithelial Lesions
8.1.1. Molecular Changes. We use the term “serous tubal
intraepithelial lesions” (STILs) to describe a spectrum of
epithelial changes ranging from normal appearing tubal
epithelium,expressingp53,tolesionswithincreasingdegrees
of cytologic atypia that fall short of an STIC (Figure 2).
Others have reported these changes as tubal intraepithelial
lesions in transition (TILT) [37]. Characterization of STILs
has become a central focus of several groups, including
ours, in order to determine the nature of these lesions and
their relationship to STICs, speciﬁcally whether these are the
earliest steps in the carcinogenic process. A 2007 study [38]
sought to examine the relationship of what was designated
“p53signatures,”characterizedbyhighp53immunostaining,
deﬁned as strong nuclear staining obscuring nuclear detail in
at least 12 consecutive secretory nuclei in benign-appearing
epithelium, and STIC. The fallopian tubes from three groups
of women were included in this series: (1) 41 women
with BRCA1 or BRCA2 mutations undergoing BPSO, (2)
58 consecutive women undergoing procedures for other
gynecologic disease, and (3) 17 women already identiﬁed
to have STICs, all of which were shown in a previous
study to be associated with pelvic serous carcinoma [27].
All ﬁmbriae were sectioned using the SEE-FIM protocol.
Sections were examined for prevalence of p53 signatures.
Similar percentages of p53 signatures were found in the
benign BPSO specimens from BRCA+ women versus group
2 (24% and 33%, resp.) and were most often found in
the ﬁmbriated end of the tube. Nine of the 17 STICs
(53%) contained at least one p53 signature and multiple
p53 signatures were found in tubes containing STICs at
twice the frequency found in nonneoplastic tubes. Staining6 Journal of Oncology
(a)
(b)
Figure 1: Serous tubal intraepithelial carcinoma (STIC). (a)
The morphological features of a small STIC showing papillary
architecture with intraepithelial carcinoma cells, many of which are
detached and are able to freely disseminate onto ovaries, pelvic, or
peritoneal wall. (b) The p53 immunohistochemistry demonstrates
that all intraepithelial carcinoma cells are intensely positive for p53
nuclear immunoreactivity. In contrast, the normal-appearing tubal
epithelial cells ﬂanking the STIC are negative for p53.
of a subset of tissues containing p53 signature, STIC, or
serous carcinoma revealed the colocalization of γ-H2AX,
an immunohistochemical marker of double-stranded DNA
damage, with p53.
Another study from the same group compared the
prevalenceofp53signaturesinfallopiantubesversusovarian
cortical inclusion cysts in BRCA+ women [39]. Cases con-
sisted of consecutive BPSOs performed in BRCA+ women.
Controls, taken from a prior study, were a consecutive series
of women free of ovarian cancer, having surgery for other
gynecologic conditions, who had either tested negative for
BRCA mutations or were untested. All tubes and ovaries
were submitted entirely, and the SEE-FIM protocol was used
for examining the ﬁmbriae. The proportions of specimens
that showed at least one p53 signature were similar between
cases and controls (38% and 33%, resp.). No CICs were
found to contain p53 signatures. Sixty-six percent of the p53
signatures in cases stained positive for γ-H2AX; staining for
γ-H2AX in the p53 signatures of controls was not reported.
8.1.2. Hormonal Changes. One of the prevailing theories
of ovarian epithelial carcinogenesis is that of “incessant
ovulation” as a potential causative role in these cancers.
Ovulation has been suggested to cause genotoxic damage in
the ovarian surface epithelium where ovarian cancers have
traditionally been thought to originate; the recent ﬁndings
of colocalization of γ-H2AX with p53 staining in STILs and
STICs in the ﬁmbria, adjacent to the ovarian surface, is
(a)
(b)
(c)
Figure 2: Serous tubal intraepithelial lesion (STIL). (a) The
morphological features of an STIL identiﬁed in a young cancer-free
BRCA mutation carrier. The epithelium shows mild nuclear and
architectural atypia but not to the level of a classical STIC. (b) An
immunohistochemicalstainforp53showsoverexpressioninseveral
consecutive secretory cells. (c) An immunohistochemical stain for
Ki-67 shows a low proliferation index.
therefore highly intriguing and will be important to explore
further.
A recent study exploiting genetic microarray technol-
ogy compared the expression proﬁles of normal-appearing
fallopian tube epithelium of BRCA+ mutation carriers and
h e a l t h yc o n t r o l st os e r o u sc a r c i n o m a s[ 40]. Fallopian tube
epithelium samples from the BRCA+ group (but not the
normal controls) were found to cluster closely with serous
carcinoma samples. In particular, BRCA+ fallopian tube
epithelium taken during the luteal phase (versus follicular
phase) expressed gene proﬁles most similar to those of the
serous carcinoma tissues. Two diﬀerentially expressed genes,
SKIL(ski-like),anoncogene,andDAB2,atumorsuppressor,
emerged as candidates that have been implicated in the
tumorigenic process [41, 42]. SKIL was found to be overex-
pressed, and DAB2 underexpressed, in serous carcinoma and
BRCA+ luteal fallopian tube epithelium, relative to BRCA+
follicular fallopian tube epithelium samples, suggesting that
the hormonal milieu during the luteal phase, particularly in
BRCA+ carriers, may predispose to a carcinogenic process in
the fallopian tube epithelium. The extent to which hormonal
changes during the luteal phase represent a transitory
phenomenon, and the manner in which the fallopian tube
epithelium might retain a more permanent imprint of such
cyclical ﬂuctuations, is unclear.
Tubal-mucosal morphology is known to be inﬂuenced
by hormones [15], although these changes have not been
precisely quantiﬁed. Presumably, the endogenous and exoge-
nous hormonal milieu plays a key role in the molecularJournal of Oncology 7
alterations of the fallopian tube epithelium, varying with
age and menopausal status. Evidence from epidemiological
studies provided further supports the role of hormonal
exposures in aﬀecting risk of ovarian cancer. It has been
wellestablished in epidemiological studies that use of oral
contraceptive pills (OCP) protects against the development
of ovarian cancer; use for ﬁve or more years reduces risk
by approximately 50% [43, 44]. Parity has also been shown
in numerous studies to be protective, conferring a 30%–
60% decreased risk compared to nulliparity [45]. Two
theories have been postulated to explain these ﬁndings:
that ovulation causes repetitive cell damage/repair which
over time increases the risk of mutations or that increasing
exposure to gonadotropin-releasing hormones (represented
by lower OCP use and parity, or increased ovulatory cycles)
may be the mechanism by which ovarian cancer risk is
increased. But studies attempting to ﬁnd a correlation
between number of ovulatory cycles and accumulation of
p53 mutations in ovarian cancers have been contradictory
[46–48]. Schildkraut et al. (1997) examined the ovaries from
197womenwithinvasiveovariancancerandfoundthatcases
overexpressingp53(53%)wereexposedtosigniﬁcantlymore
ovulatory cycles than those cases that did not overexpress
p53. However, a study by Webb et al. examined 234 cases of
invasive ovarian cancer and found no associations between
p53 overexpression and other factors including years of
ovulation, parity, family history of ovarian cancer, or age.
One cross-sectional study examined the association between
factors including parity, history of breast cancer, prior
chemotherapy, smoking history, tamoxifen use, age at ﬁrst
birth, age at time of oophorectomy, BMI, age at menarche,
and oral contraceptive use (never versus ever) obtained from
medical record review and the presence of p53 signatures in
the tubes of 75 BRCA+ mutation carriers [49]. Thirty eight
percent of the tubes showed at least one p53 signature, and
parity was signiﬁcantly associated with the presence of p53
signatures. Due to the cross-sectional nature of the study
temporality could not be assessed.
8.1.3. Cortical Inclusion Cysts. Several studies comparing the
prevalence of CICs in “high-risk” prophylactically removed
ovariesversusnormal-riskovarieshavereportedinconsistent
ﬁndings [50]. One study comparing morphology of ovarian
surface epithelium of 64 women with a family history of
ovarian cancer with 30 women without a family history
found signiﬁcantly more CICs in the high-risk group [51],
while others have found no signiﬁcant diﬀerence in the
frequency of CICs. CICs also appear to increase with age in
both high-risk and normal-risk women, and this needs to
be taken into consideration when evaluating its signiﬁcance
as a precursor lesion [50]. Barakat et al. [52] examined
ovarian tissues from 18 BRCA1 mutation carriers and 20
age-matched controls and found no signiﬁcant diﬀerences
in frequency of inclusion cysts or other morphological
alterations. Immunohistochemical staining for p53, ERBB-
2, and Ki67 of the CICs also showed no diﬀerence in
expression between cases and controls. In a cross-sectional
studyexaminingtherelationshipbetweendemographicvari-
ables and the presence of CICs in 74 bilateral prophylactic
salpingo-oophorectomies (BPSOs) from BRCA1/2 mutation
carriers, Folkins et al. [53] found women with ≥7v e r s u s<7
CICs per ovary pair had signiﬁcantly older age at childbirth
and menopause, older age at surgery, and higher body
mass index (BMI). Limitations of this study include the
small sample size, which prevented the analyses from being
adjusted for confounders, such as age, and the retrospective
collection of information on risk factors from medical
records.
8.1.4. Future Directions. Large, well-powered studies with
uniform sectioning methodology are needed to better deﬁne
the prevalence of STICs and STILs in specimens from high-
risk women and the general population, and to determine
the incidence of subsequent peritoneal cancer. Further
prospective data is needed to assess interactions between
exposures and these lesions. Animal experiments could assist
in validating the temporality of these precursor lesions to
the development of ovarian serous carcinoma, as this type
of study would not be feasible in clinical studies. The genetic
changes accompanying and preceding these lesions may then
be able to be targeted in prevention studies. In addition,
a validated classiﬁcation of STIL would help both internal
validity and generalizability of studies.
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